Nexalin Technology Files S-1/A Amendment
Ticker: NXL · Form: S-1/A · Filed: Jun 26, 2024 · CIK: 1527352
Sentiment: neutral
Topics: sec-filing, registration, amendment
TL;DR
Nexalin Tech filed an S-1/A update, still working on their registration. Watch for next steps.
AI Summary
Nexalin Technology, Inc. filed a Pre-Effective Amendment No. 3 to its Form S-1 Registration Statement on June 26, 2024. The company, incorporated in Delaware with its principal executive offices in Houston, TX, is registering securities under the Securities Act of 1933. This filing is an update to their ongoing registration process.
Why It Matters
This amendment to Nexalin Technology's S-1 filing indicates ongoing efforts to register securities, which is a step towards a potential public offering or other significant corporate actions.
Risk Assessment
Risk Level: medium — S-1/A filings often precede significant corporate events like IPOs or secondary offerings, which carry inherent market and execution risks.
Key Numbers
- 333-279684 — SEC File Number (Identifies the specific registration statement)
- 3845 — SIC Code (Classifies the company's industry as Electromedical & Electrotherapeutic Apparatus)
Key Players & Entities
- Nexalin Technology, Inc. (company) — Registrant
- June 26, 2024 (date) — Filing Date
- 333-279684 (registration_number) — SEC File Number
- Mark White (person) — Chief Executive Officer
- 1776 Yorktown, Suite 550 Houston, TX 77056 (address) — Principal Executive Offices
- Martin S. Siegel, Esq. (person) — Legal Counsel
- Andrew M. Tucker, Esq. (person) — Legal Counsel
FAQ
What is the purpose of this Pre-Effective Amendment No. 3 to the Form S-1 Registration Statement?
This amendment is filed to update and supplement the information previously provided in the initial Form S-1 registration statement, as required by the SEC during the registration process.
When was this amendment filed with the SEC?
This amendment was filed with the Securities and Exchange Commission on June 26, 2024.
What is Nexalin Technology, Inc.'s primary business classification?
Nexalin Technology, Inc. is classified under Standard Industrial Classification code 3845, which pertains to Electromedical & Electrotherapeutic Apparatus.
Who is the Chief Executive Officer of Nexalin Technology, Inc.?
Mark White is the Chief Executive Officer of Nexalin Technology, Inc.
Where are Nexalin Technology, Inc.'s principal executive offices located?
Nexalin Technology, Inc.'s principal executive offices are located at 1776 Yorktown, Suite 550, Houston, TX 77056.
Filing Stats: 4,585 words · 18 min read · ~15 pages · Grade level 14.7 · Accepted 2024-06-26 13:36:40
Key Financial Figures
- $7,000,000 — CTUS NEXALIN TECHNOLOGY, INC. Up to $7,000,000 of Common Stock We are offering on a
- $0.001 — s up to $7,000,000 of our common stock, $0.001 par value per share. We are offering ea
- $2.26 — at an assumed public offering price of $2.26 per share. The securities will be off
- $5,783 — ASC 810”), the Company recognized $5,783 of equity method investment income from
Filing Documents
- nexalintech_s1a3.htm (S-1/A) — 652KB
- nexalintech_ex1-2.htm (EX-1.2) — 114KB
- nexalintech_ex5-1.htm (EX-5.1) — 9KB
- nexalintech_ex10-15.htm (EX-10.15) — 26KB
- nexalintech_ex10-16.htm (EX-10.16) — 191KB
- nexalintech_ex23-1.htm (EX-23.1) — 2KB
- img_001.jpg (GRAPHIC) — 7KB
- ex5-1_001.jpg (GRAPHIC) — 4KB
- 0001829126-24-004428.txt ( ) — 1011KB
RISK FACTORS
RISK FACTORS 17 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA 52
USE OF PROCEEDS
USE OF PROCEEDS 54 DIVIDEND POLICY 55 CAPITALIZATION 56
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 58 PLAN OF DISTRIBUTION 61 LEGAL MATTERS 66 EXPERTS 66 WHERE YOU CAN FIND ADDTIONAL INFORMATION 66 INCORPORATION OF CERTAIN INORMATION BY REFERENCE 67 You should rely only on the information contained in this prospectus or any prospectus supplement or amendment. Neither we, nor the Placement Agent, have authorized any other person to provide you with information that is different from, or adds to, that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the Placement Agent take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of any securities in any jurisdiction in which such offer is unlawful. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this public offering and the distribution of this prospectus applicable to that jurisdiction. i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (“SEC”). It omits some of the information contained in the registration statement and reference is made to the registration statement for further information with regard to us and the securities being offered hereby. You sho